New injection techniques

As we get read for the introduction of oral medications, pegylated interferons and more monoclonal antibodies, the interferon companies (Bayer, Biogen Idec, EMD Serono / Pfizer and Novartis) as well as Teva, are trying to develop new injection techniques (disposable needles, "EpiPen"-type injectors, new technologies ala RebiSmart and more infrequent dosing regimens, such as very other day Copaxone, which, by the way, needs to combat the same difficulties of confusing Betaseron/Extavia).

Despite this, the Lancet Neurology Reflection and Reaction by Pittock (online September 11, 2009) has a picture of someone drawing uo Betaseron with a needle, like in the past; where is the new autoinjector (BetaLite) system?

While we are looking back, Pittiock's 2007 Lancet editorial Interferon

beta in multiple sclerosis: how much BENEFIT? also had an (for the American audience, at least) upside down cervicall MRI.

I guess things aren't as they seem.

- Dr. Daniel Kantor, MD BSE
Medical Director
Neurologique

info@neurologique.org
www.neurologique.org